Beyond Borders: A Case Report of Melioidosis and the Urgent Need for Tropical Disease Vigilance in Western Healthcare
Main Article Content
Abstract
Melioidosis, caused by the Gram-negative bacillus Burkholderia pseudomallei, is increasingly recognised as a threat beyond its endemic regions of Southeast Asia and Northern Australia. Globalisation, international travel, and environmental change have facilitated its emergence in Western countries, where it remains underdiagnosed due to limited clinical awareness and microbiological preparedness. We report a case of imported melioidosis in a 52-year-old French male who returned from Thailand with an initial pulmonary presentation, followed by central nervous system involvement manifesting as focal pachymeningitis. Diagnostic efforts were hindered by the pathogen’s misidentification via MALDI-TOF mass spectrometry, due to biosecurity-related database restrictions excluding B. pseudomallei. Accurate diagnosis was achieved only after relapse and referral to a national reference laboratory. This case underscores the diagnostic and therapeutic challenges posed by tropical pathogens in non-endemic settings and the need to adapt clinical protocols, microbiological platforms, and physician training in Western healthcare systems. The emergence of such infections highlights the shifting landscape of global health, shaped by travel, climate change, and evolving microbial ecologies. Greater vigilance is warranted to prevent delayed diagnoses and optimise management of imported and emerging infectious diseases.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Carlson CJ, Albery GF, Merow C, et al. Climate change increases cross-species viral transmission risk. Nature. 2022;607(7919):555–562.
3. Wu X, Lu Y, Zhou S, Chen L, Xu B. Impact of climate change on human infectious diseases: Empirical evidence and human adaptation. Environ Int. 2016;86:14–23.
4. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383–409.
5. Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015;36(1):111–125.
6. Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev. 1991;4(1):52–60.
7. Limmathurotsakul D, Golding N, Dance DA, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1:15008.
8. Howard K, Inglis TJ. The effects of Burkholderia pseudomallei biosecurity requirements on microbiological diagnosis and research. Med J Aust. 2003;178(5):242–244.
9. Yung AP, McDonald MI. Neurological melioidosis: a review of cases from tropical northern Australia. Clin Infect Dis. 2003;36(3):392–397.
10. Limmathurotsakul D, et al. Predicted global distribution of B. pseudomallei. Nat Microbiol. 2016;1(1):15008.
11. Biggs BA, et al. Melioidosis in returning travellers: review of cases in Victoria, Australia. Med J Aust. 2014;200(2):136–138.
12. Allworth AM. Melioidosis: An imported infection seen in military personnel. Aust N Z J Med. 1986;16(5):803–807.
13. Sanford JP. Melioidosis: a persistent problem. J Infect Dis. 1980;142(3):386–389.
14. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035–1044.
15. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. PLoS Negl Trop Dis. 2010;4(11):e900.
16. Meumann EM, et al. Neuromelioidosis: neurological manifestations of melioidosis. Trop Med Infect Dis. 2019;4(1):38.
17. Lipsitz R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis. 2012;18(12):e2.